Breaking Barriers.
Protecting Brains.
Our Mission
At Bivium Biosciences, our mission is to revolutionize the treatment of neurodegenerative diseases like Multiple Sclerosis and Alzheimer’s Disease. We are doing this by delivering innovative, brain-penetrant therapeutics that provide precise and effective neuroprotection.
The Problem
Current treatments for neurodegenerative disorders often focus on secondary processes like inflammation (for MS) and aberrant plaque accumulation (for AD). While these approaches have shown some clinical promise, remissions are often short-lived and relapses are very common.
Several recent discoveries made by our team have identified key molecular players involved in the glutamate-mediated neurodegenerative cascade, uncovering novel therapeutic entry points to address the root causes of these devastating diseases.
Bivium Biosciences
Leadership Team
Philippe Deschamps
President & CEO
Phillippe Deschamps brings nearly four decades of experience to the global healthcare industry, where he has led four companies as CEO and raised over $125 million in funding.
Tara DeSilva, PhD
Scientific Inventor
Dr. Tara DeSilva is an Associate Professor at the Cleveland Clinic with 15+ years of investigating neuroinflammation and mechanisms of cell death. Tara’s groundbreaking work in neurodegeneration lies at the core of our innovative therapeutic strategy.
Brian Cogley
CFO
Financials & Milestone Roadmap
Bivium Biosciences seeks $10M via a Tier 1 Regulation A offering to fund a 3-year preclinical program, aiming to our proprietary, brain-penetrant therapeutic for neurodegenerative diseases like MS and Alzheimer’s. Milestones include the generation of brain-penetrant biologic, securing feasibility data, and obtaining FDA IND approval for Phase 1 trials.
Our current milestone roadmap is depicted below.
Year 1
Generation of preclinical inhibitor and development of in vitro target engagement assay- December 31, 2025
Years 2-3
The initial investment will be used to provide feasibility data for the brain-penetrant biologic.
Years 2-3
Further financing will be used to complete preclinical examination and submission of IND to the FDA for Phase I trials